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Tbe detection of an increasing number of cytokines 
and tbe demonstration of autocrine and paracrine 
mecbanisms perpetuating tumor growtb prompted 
tbe investigation of tbe expression of tbe cytokines 
/L-2, /L-3, /L-4, /L-5, /L-6, IFN gamma, Tac, and 
GMCSF tn prlmary lympb-node biopsies of patients 
witb peripberal T-cell Iymphoma (n = 11), 
Hodgkin's disease (n = 13), and large-cell anaplas-
tic Iymphoma (n = 6) by means of Nortbern blot 
analysts and in situ bybrldization (JSH); 15 of 28 
cases bad /L-6 message, predominantly in cases of 
Hodgkin's disease (HD) and large-cell anaplastic 
Iymphomas (LCAL). Interferongamma was found in 
about 50% of tbe cases among all enttties. Otber cy-
tokine expression was rare except two cases of HD 
witb bigb amounts of /L-4 mRNA These results indt-
cate tbat /arge amounts of growtb factor transcripts 
are present in a varlety of malignant Iymphomas. 
Tbe meaning oftbis expression is still unclear.Jt may 
be a loss of pbysiologic regulation witbin tbe cyto-
kine network wbicb may tbus influence neoplastic 
cell growtb as some cases bave a quantity of cytokine 
expression wbtcb is similar or even above tbat of 
stimulated T cells. ISH demonstrates in individual 
cases tbat tbe expresston is at least in part due to 
malignantcells. (Am]Patbol 1991, 139:1173-1180) 
Functionally heterogeneaus activated T lymphocytes, es-
pecially helperlinducer T cells, are the major source of 
lymphokines. These soluble factors mediate at least in 
part activation, proliferation, and differentiationofT and B 
lymphocytes, monocytes, and other hematopoietic 
cells. 1 
ln the B-eeil system, the construction and composition 
of lymph-node follicles, the growth of follicular Iympho-
mas with a neoplastic cell clone, and the constant coex-
istence of accessory cells give strong evidence of a cel-
lular interaction mediated by soluble factors.2·3 
The detection of autocrine or paracrine cytokine pro-
duction in some B-eeil Iymphomas may be an additional 
ground for the hypothesis of a continuous neoplastic cell 
growth.4·5 
Observations in B-eeil lymphomas2 prompted an in-
vestigation for possible cytokine expression within the dif-
ferent T-cell Iymphoma entities and Hodgkin's disease 
(HO). The mixed cellular infiltrate, which is found in T-cell 
Iymphomas and especially in HO, mirrors a cellular inter-
action between neoplastic and non-neoplastic cell com-
partments mediated by soluble factors. We investigated 
the expression of IL-2-IL-6 and of IFN gamma and gran-
ulocyte-monocyte stimulating factor (GMCSF) in total 
RNA and by means of in situ hybridization in tissue sec-
tians at the single-cell Ievei. 
Materials and Methods 
Thirty sections from primary biopsies from untreated pa-
tients were investigated. One half of the lymph node was 
formalin fixed, the other half was snapfrozen in liquid ni-
tragen; 5-.,u11 paraffin sections were stained for H&E, Gi-
emsa, PAS (periodic acid Schiff-reaction), and for Go-
mori silver impregnation. Frozen sections were used for 
immunophenotyping with monoclonal antibodies (C03, 
CD4, CD5, CD8, CD22, C025, CD30) and for in situ hy-
bridization. Gases of Hodgkin's disease were classified 
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according to the Rye classification,6 cases of T-celllym-
phomas were classified according to the updated Kiel 
classification?·8 Eleven cases were diagnosed as pe-
ripheral T -celllymphomas, 13 cases as HO and 6 cases 
as large-cell anaplastic Iymphoma (LCAL), 3 of which 
were of T -cell type and 2 of B-eeil type. One LCAL could 
not be classified conceming its cellular origin. 
RNA Preparation and Northern Blotting 
Frazen tumor material was homogenized and sus-
pended in guanidine thiocyanate buffer according to the 
method of Chirgwin et al.,9 followed by cesium-chloride 
gradient centrifugation.10 20 ~g of total RNA per lane was 
size-fractionated by electrophoresis in 6% formaldehyde 
and 1 .5% agarase gels.11 Before RNA transfer to nylon 
membranes 12 (Hybond, Amersham, Braunschweig, 
FRG), the gels were stained with ethidium bromide to 
verify equal quantities and integrity of RNA. Equal 
amounts of total RNA of stimulated peripheral blood lym-
phocytes (PBL) phorbol-urgistate-A3 acetate 1 0 ng/ml, 
Sigma, Munich, FRG, Ca-ionophore-A 23187, Sigma, 
100 ng/ml) were used as controls. 
Hybridization 
Prehybridization was performed in 50% formamide, 2 x 
SSC, 0.1% sodium dodecyl sulfate, 20 mM vanadyl-
ribonucleosid-complex, 200 ~g/ml salmon sperm ONA 
(Boehringer, Mannhein, FRG), 200 J.Lg/ml yeast-tRNA 
(Boehringer), 5 x Denhardts solution, 1 0% dextran sul-
fate for 4 hours to 6 hours at 58°C; 5 ng/ml of alpha 32p-
labeled (Amersham) anti-sense-cRNA probe was added 
and hybridization was performed for 12 hours to 16 
hours.13 
Filters were washed 2 x 5 minutes, 2 x SSC, 0.1% 
SOS at room temperature, 2 x 30 minutes, 2 x SSC, 
0.1% SOS at 65°C, 2 x 1 0 minutes, 0.2% SSC, 0.1% SOS 
at 650C to 7rtC. 
Filters were exposed to Kodak-X-omat film (Kodak, 
Rochester, USA) for 8 hours to 72 at - 70°C. 
After exposure, RNA-blots were stripped of 32p-
labeled probes by incubation in boiling solution of 0.1% 
SOS and subsequent cooling to room temperature. Blots 
were reused 4 to 5 times. 
ln Situ Hybridization 
Five-~ cryostat sections were pla~ed on 2% 3-(Tri-
ethoxysilyl)-propylamine (Merck, Oarmstadt, FRG) acti-
vated slides and fixed in 4% paraformaldehyde (Merck), 
0.1% glutaraldehyde (Merck) in PBS (ph 7 .5) for 60 min-
utes at room temperature and stored in 70% ethanol. 
Rehydrated slides were acetylated in 0.1% triethanol-
amine (ph 8.0) (Sigma), 0.25% acetic anhydride (Sigma) 
for 10 minutes, and postfixed in 4% paraformaldehyde 
for 1 0 minutes, dehydrated in a series of graded ethanol 
and finally air dried. 
Hybridization was performed in a solution containing 
4 x SSC (1 x SSC = 0.15 NaCI, 0.015 M trisodium 
citrate), 10% dextran sulfate (Sigma), 20 mM vanadyl-
ribonucleoside-complex, 200 J.Lg/ml yeast-tRNA (Boe-
hringer), 200 J.Lg/ml salmon-sperm-ONA (Boehringer}, 
500 J.Lg/ml bovine serum albumin (Sigma), 50% deion-
ized formamide (BRL), 10mM Tris-HCL (pH 8,0), 1 mM 
EOTA, 5 ng alpha 35S-UTP (Amersham) labeled an-
tisense or sense riboprobe (specific activity: 1-2 x 10S 
cpm/J.LQ) were added to 20 J.LI hybridization solution. ln-
cubation time was 4 hours to 16 hours in a humidified 
chamber at 500C. 
Washing was performed in 4 x SSC at room temper-
ature for 1 0 minutes, 2 x SSC at 5~ for 30 minutes, 2 x 
SSC, 20 J.Lg/ml RNase A (Boehringer) at 3-rC for 30 min-
utes, 0.2 x SSC, 1 0 mM OTT (Sigma) at 5~C for 30 
minutes. Slides were then rinsed twice in 70% ethanol, 
200 mM ammonium-acetate (ph 5.4) for 10 minutes, de-
hydrated, and air dried. 
Slides were subsequently dipped in llford K2 Emul-
sion, stored for 3 days at 4°C, developed in Kodak 019 
developer and Giemsa stained. 
Probes 
The cONAs of IL-2, 14 IL-3, 15 IL-6,16 GMCSF, 17 IFN 
gamma18 and TAC19 were cloned and sequenced by 
one of us (W.S.) and were identical to the published se-
quences. The cONAs of IL-420 and IL-521 were originally 
obtained from British Biotechnology and were identical to 
the published sequences. 
The cDNAs of the coding regions of IL-2 to IL-6, 
GMCSF, gamma-IFN, and TAC were subcloned into 
transcription vectors (PSPT 18/19, Boehringer) 
The 32P and 35S labeled sense and antisense-cRNA 
probes were generated in in vitro transcription experi-
ments with T7 RNA-Polymerase (Boehringer) to a spe-
cific activity of 1-5 x 10S cpm/J.Lg cRNA. 
Results 
The detailed diagnoses of the investigated Iymphomas 
based on morphology and immunophenotypic data as 
weil as the mRNA cytokine expression are given in Table 
1. lnvestigation of cytokine expression of total RNA con-
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Table 1. /mmunophenotype and mRNA Expression in Peripheral T-cell Lymphoma, Hodgkin's Disease, and Large-cell 
Anaplastic Lymphoma 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
Diagnosis 
T-pleom 
T-pleom 
T-pleom 
T-pleom 
T-pleom 
T-pleom 
*T-AILD 
T-AILD 
T-AILD 
T-AILD 
Lennert's 
LCAL-B-type 
LCAL-B-type 
LCAL-0-type 
LCAL-T-type 
*LCAL-T-type 
LCAL-T-type 
HDLP 
HDNS 
HDNS 
HDNS 
*HDNS 
HDNS 
HDNS 
HDNS 
HDMC 
HDMC 
*HDMC 
HDMC 
HOLD 
* Additional investigation by ISH. 
Northern-mRNA expression** 
-: no expression detectable. 
IL-2 
nd 
nd 
nd 
nd 
nd 
nd 
+: detectable signal after 48h exposure. 
IL-3 
nd 
+ 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
nd 
+ 
+ 
+ + : strong or very strong signal after 48h exposure. 
IL-4 IL-6 GM-CSF IFN g 
+ 
nd nd 
+ 
+ 
+ 
++I++* + 
++ 
+ 
++ + 
+ + 
+ + 
-1+* +I+* 
+ nd nd 
++ nd nd 
++ + 
++ + 
-1+* +I+* + 
++ nd nd 
nd nd 
++ nd nd 
++ + nd nd 
+ 
-I- * + 
++ 
+, + +: refer to relative intensity of the message, with + + being comparable to PMAIPHA-stimulated PB I. 
nd: not determined. 
T-pleom: peripheral T-celllymphoma pleomorphic. 
T-AILD: T-celllymphoma of angioimmunoblastic type. 
Lennert's: Lennert's Iymphoma. 
LCAL: large-cell anaplastic Iymphoma. 
HDLP: Hodgkin's disease-lymphocyte predominant. 
HDNS: Hodgkin's disease-nodular sclerosis. 
HDMC: Hodgkin's disease--mixed cellularity. 
HOLD: Hodgkin's disease-lymphocyte depleted. 
tent in peripheral T -celllymphomas (n = 11: AILD, pleo-
morphic T -cell Iymphoma, Lennert's Iymphoma) lacked 
positivity for IL-2 and IL-4. A single case had detectable 
amounts of IL-3. This case was, except for a single LCAL, 
the only one with a clear GMCSF message. 
IL-4 mRNA was found in two cases (Hodgkin's dis-
ease, mixed cellularity; HDMC and Hodgkin's disease, 
lymphocyte depletion type; HOLD) of the whole series of 
Hodgkin's and non-Hodgkin's Iymphomas (NHL) (Figure 
1 ). A marked IL-6 message was found in 7 of 29 cases 
whereas 8 other cases had moderate amounts of this 
cytokine (Rgure 2). The equalloading of the lanes as weil 
as the integrity of RNA is documented in Figure 3. 
Out of a total of 19 cases, 2 cases of HD had a clear 
IL-3 message. Various amounts of IFN-gamma were 
found in 11 of 23 cases within all entities (Figure 4 ). 
Four cases (2 HO: no. 22 and 28, 1 LCAL: no.16, 1 
AILD: no. 7) were additionally investigated by the in situ 
hybridization technique on cryostat sections with probes 
for IL-4, IL-5, and IL-6. 
IL-4 message could be detected in one case of 
Hodgkin's disease, nodular sclerosis type (HDNS) in 
some small lymphoid cells. Hodgkin (H) and Reed-
Sternberg (RS) cells were negative. IL-5 messagewas 
visible in both cases of HO with varying numbers of pos-
itive lymphocytes and additional positive H and SR cells. 
IL-6 was detectable in the examined cases of T-AILD 
(no. 7) and LCAL (no.16) in the atypical T cells and in both 
cases of HO with moderate numbers of positive lympho-
cytes and positive H and SR cells in HO (Figure 5a). 
Using the sense probe for control, we achieved a nearly 
complete negative signal (Figure Sb). 
1176 Merz et al 
AJP November 1991, Vol. 139, No. 5 
Figure 1. /L-4 expression in cases oj Hodgkin's disease. 1-3: 
Hodgkin's disease, nodu/ar scleros;s'l2·n.24; 4: Hodgkiri's disease, 
mi.xed ce/lularit)ll; 5: Hodgkin 's disease, ~vmphocyte depletionu; c: 
control, RNA.from PHNPMA stimulated PBL; a/llanes contained 
10 ,.,.g of total cellu/ar RNA; e:xposure time: 48 h. 
Discussion 
Most cases of HO are characterized by a mixed cellular 
infiltrate of lymphocytes, plasma cells, eosinophils, mac-
rophages and H and SR cells. Genotypic data gave ev-
idence that in the majority of cases only a minor popula-
tion, most probably comprised of H and SR cells, is con-
fined to the clonally proliferating cell clone.22·25 At least 
some of these were shown to express genotypic and 
phenotypic properties of the T-celllineage.26-31 Contrary 
to HO, peripheral T-celllymphomas mostly consist of a 
homogeneaus neoplastic cell population comprising the 
majority of the cellular infiltrate.8·32 LCAL has some phe-
notypic and genotypic features of HO and may even be 
accompanied by a host cellular infiltrate of eosinophils 
and plasma cells.33 Whether these different or related 
entities have similarities in their ability to produce effective 
cytokines which may be involved in the microenviron-
mental structure and in tumor growth is of interest. More-
over, clinical symptoms frequently prominent in HO may 
also be due to an uncontrolled or overwhelming cytokine 
production. 
ln this study we show that peripheral T-cell Iympho-
mas and cases of HD may express a variety of growth 
factors. Whereas expression of IL-2 was not found and 
IL-4 expression occurred in just two cases of HOLD, a 
marked heterogeneity in the expression of IL-6 was de-
tected, especially in HO and LCAL. These data are in 
accordance with Tabibzadeh et al.,34 who demonstrated 
a variable amount of IL-6 proteinindifferent cases of HO 
and NHL by means of immunohistochemistry. 
Besides a limited expression of GMCSF in 2 T -cell 
Iymphomas and 1 HD, about 40% of the cases had dif-
ferent amounts of IFN-gamma. ln previous studies both 
cytokines were detected in HD-celllines.35-37 
Surprisingly, not a single Iymphoma could be demon-
strated to express IL-2 message by Northern blotting. At 
least some cases of LCAL with T -cell properties were 
expected to express this cytokine as these Iymphoma 
cells are known to carry markers of cell activation with 
expression of CD30, CD25, and HLA class II antigens. 
However, it was demonstrated that IL-2-R-(TAC)-
Figure 2. /L-6 expression in cases oj HD and 
LCAL. c: control, RNA jrom PHNPMA acti-
vated PBL; NS: Hodgkin 's disease, nodular 
sclerosw6 ; NS: Hodgkin :S disease, nodular 
sclerosw7 ;MC: Hodgkin :S disease, mi.xed cel-
lularityZ9; NS: Hodgkin's disease, nodular 
scleros;s'l8 ; LCAL: Large-cell anaplastic Iym-
phoma 20; IPHD: Hodgkin 's disease, lympho-
cyte predominant 21; al/ lanes contained 10 
1-18 total RNA exposure time 48 h. 
Figure 3. Photograph of tbe ethidium bromide-stained gel. Tbe 
corresponding blot is shown in Figure 2. 
expression is not necessarily coupled with a responsive-
ness for IL-2.38 
Our results differ from a recently published study in 
which IL-2 message was reported in 20 of 20 investi-
gated cases of C025 positive Iymphoma, 9 of which were 
characterized as LCAL.39 That investigation was per-
formed with in situ hybridization technique. By combining 
immunohistochemistry with in situ hybridization Peuch-
meur et al. could detect the IL-2 production only in reac-
tive T -cells and suggest a paracrine IL -2 involvement. 
Thus Northern blot may not be sensitive enough to detect 
such small amounts of a cytokine. 
IL-3, which is known tobe a potent multilineage factor 
Figure 4. lnteiferon gamma expression in 
cases of peripberal T-celllympboma, HD, and 
LCAL. 1: T-AILD 10; 2: T-pleom5 ; 3: LCAL, 
T-type18; 4: T-AJW13; 5: Hodgkin's disease, 
nodu/ar scleros;s25; c: control RNA of PHN 
PMA stimulaled PBL. 
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of early hematopoiesis, 40 was detected in 3 of 19 exam-
ined cases (2 HO, 1 T-celllymphoma), which further doc-
uments the heterogeneity of these neoplasms. 
Two cases with a strong IL-4 signal were diagnosed 
as HOMC and HOLD. The last case lacked any typical B-
or T -cell antigen expression. However, compared with 
stimulated peripheral T -cells the intensity of the signal in 
the Northem blot and the homogeneity of the cellular in-
filtrate may indicate that this growth factor is produced by 
the tumor cells themselves (Figure 1 ). 
ln situ hybridization for IL-4, IL-5, and IL-6 in HO and 
LCAL demonstrates in individual cases that the expres-
sion is due to lymphocytes and H and SR cells. Demon-
stration of IL-4 in case no. 22 (HDNS) by in situ hybrid-
ization visualized some positive lymphocytes (up to 
10%), whereas Hand SR cells were invariably negative. 
ln this case IL-4 mRNA could not be detected by means 
of Northern hybridization in whole tissue RNA. 
The in situ hybridization results underline that IL-5 
mRNA production is not only confined to H and SR cells4 1 
but may also be found in activated lymphocytes, which 
are known tobe the main source of IL-5 production.42. 
The reliability of these results was documented in 
cases no. 7 (AILD) and no. 22 (HDNS) using a probe for 
IL-6; both cases had clear-cut signals for IL-6 in Northern 
blots. A positive signal was also found in both cases by in 
situ hybridization in the majority of atypical lymphocytes 
(case no. 7) in some small lymphocytes and more fre-
quently in Hand SR cells (case no. 22) (Rgure 5). 
These results demonstrate that even small amounts of 
highly effective cytokines could be detected by in situ 
hybridization even in those cases where Northem blot 
analysis gave negative resu~s. lt thus seems possible 
that the microenvironmental structure and probably even 
tumor growth can be modulated by locally acting cytok-
ines. 
The high number of individual cytokines found in the 
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Figure 5. a,b:ln situ hybridizationjor IL-6 in 
cases of Hodgkin s diseast?·s positive signa/ is 
jound predominantly over /arge Hodgkin-
like cells; (b) shows the same case as (a) using 
a sense probe as control. 
total RNA of the whole cellular content can be interpreted 
as due to a loss of the physiologic regulation within the 
cytokine network and thus may be a sign of neoplastic 
cell growth. However, it is known that even small amounts 
of cytokines can act as potential Stimulators or inhibi-
tors.431nvestigations on celllines of HO and some T-cell 
Iymphomas especially have demonstrated the expres-
sion of a number of growth factors like IL-1,44 IL-2,45 IL-
5,42 IL-6,34·46·47 GMCSF,36 TGFß,48 and TNF/L T.49 lt is 
still a matter of speculation whether these cell lines use 
these factors as autocrine growth promoters or whether 
they may even grow independently. 
The present results document a strong heterogeneity 
in cytokine expression even among Iymphoma typesthat 
were morphologically homogeneaus and referred to as 
distinct Iymphoma entities. However, cytogenetic studies 
in T -celllymphomas and HO describe an enormaus num-
ber of different chromosomal aberrations. 50-52 lt is thus 
interesting to speculate on a lymphoma-specific cytokine 
expression which may not only be responsible for de-
fined clinical symptoms but may also influence the indi-
vidual cellular composition of malignant Iymphomas and 
their growth behavior. 
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